LUMC, Genos and Ludger have been instrumental in contributing to scientific knowledge in the glycomics field, and have been co‐partners in several EU funded projects (HighGlycan, IBD‐BIOM and GlyCoCan) at various stages of translational medical glycomics. Initially, they developed sorely needed technology, then they discovered glycan biomarkers and now they aim to bring forward the most promising biomarker candidates into clinical diagnostics
Amsterdam Medical Center
Department of Urology (Prof. Jean de la Rosette MD, Theo de Reijke MD
Leiden University Medical Center (LUMC)
LUMC (academic group and the GlySign Consortium leader). Prof. Manfred Wuhrer’s research team focusses on clinical glycomics applications in the fields of immune disorders, colorectal cancer and human longevity. Prof. Wuhrer is coordinating the European HighGlycan FP7 project that has given rise to high throughput glycomics technologies that are currently being used for discovery of glycosylation clinical biomarkers of disease in other EU‐funded research programmes including IBD‐BIOM (for inflammatory bowel diseases) and GlyCoCan (for colorectal cancers).
Genos (SME) specialises in the development and application of glycoanalytical techniques for large scale glycomic studies of human plasma proteins. Prof. Gordan Lauc (CEO) led the first large‐scale studies of the human plasma glycome (in 2009) and human IgG glycome (in 2011), which were the basis for the subsequent first genome‐wide association studies of the human glycome. Genos’s glycomics research has generated several international patents relevant to Precision Medicine including IP for identification of glycan biomarkers for the MODY‐subtype of diabetes (patent # WO2012042020 A2) and for pancreatitis, sepsis and pancreatic cancer (patent # WO2009044213 A1).
Max Planck Institute of Colloids and Interfaces
Max Planck Gesellschaft
Dept. of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Berlin (daniel Kolarich)
Ludger (SME) is a specialist in the development and use of glycomics technology to support: (a) QbD (Quality by Design) based biopharmaceutical realisation and (b) medical glycomics (with a focus on high throughput glycomics of blood, saliva and solid tissues). Dr Daryl Fernandes (Chief Executive) was involved in the development of the glycoanalysis technology used in the seminal study in which disease‐specific changes in the glycan patterns of human serum IgG of patients with rheumatoid and osteoarthritis were first discovered (Parekh et al, 1985).
Department of Experimental Immunohematology (Gestur Vidarsson, PhD, Prof. Ellen van der Schoot)
Research and Development Team (Simon Charnock, PhD)